WebFeb 24, 2024 · Introduction. Statins reduce cardiovascular disease events in primary and secondary prevention, in men and women, and across all age groups. 1 2 Systematic reviews and meta-analyses of randomised trials have confirmed the safety of statins. 3 Although severe adverse effects are rare, statins increase the risk of myopathy (absolute … WebThe summary of the 2012 Cholesterol Treatment Trialists (CTT) meta-analysis is unique because it shows trial results according to baseline risk.3 For nonfatal stroke and …
MetaQTL: a package of new computational methods for the meta …
WebNov 13, 2010 · Background: Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals. We aimed to assess the safety and efficacy of more intensive lowering of LDL cholesterol with statin therapy. Methods: We undertook meta-analyses of individual participant data from … WebFeb 2, 2024 · In 2005, in a participant-level meta-analysis of large randomised controlled trials, the Cholesterol Treatment Trialists' (CTT) Collaboration conclusively showed that for most patients HMG-CoA reductase inhibitors (statins) reduced major adverse cardiovascular events.1 Since then, generic versions of commonly used statins have become available. … t shirt with black cat on side
Analyses of Cancer Data from Three Ezetimibe Trials NEJM
WebAug 26, 2024 · PARADISE-MI Trial - Win Ratio Analysis. Presented by Otavio Berwanger (Heart Hospital (HCor), Sao Paulo, BR) 29 August 2024. HOT LINE SESSION 9. Evidence synthesis on clinically important questions CTT meta-analysis of the effects of statins on muscle symptoms. Presented by Colin Baigent (University of Oxford, Oxford, UK) WebMay 18, 2016 · The landmark Cholesterol Treatment Trialists' (CTT) meta-analysis projected a 21% reduction in major vascular events per 1 mmol/L reduction in LDL-C with statins over a median of approximately 5 years of follow up. 13 In the aforementioned trials, 2,3 PCSK9 inhibitors achieved an LDL-C reduction of 1.83 mmol/L and 1.89 mmol/L for … WebFeb 8, 2024 · “This risk reduction would be expected to be higher in high-risk patients.” As such, the CTT meta-analysis makes the case for statin therapy in at-risk individuals regardless of their age, provided the benefits outweigh the harms and the patient accepts long-term treatment, say Cheung and Lam. Potential For Real Gains in Older Patients phil swanson trombone